Prosensa Holding NV (RNA)

18.65
0.00 (0.00)
Prev Close 18.65
Open 18.54
Day Low/High 18.46 / 18.69
52 Wk Low/High 4.12 / 22.80
Volume 315.67K
Avg Volume 307.00K
Exchange
Shares Outstanding 36.12M
Market Cap 673.57M
EPS -0.71
Div & Yield N.A. (N.A)

Latest News

Sarepta Updates Eteplirsen Study Results, FDA Filing Still on for Mid Year

Sarepta Updates Eteplirsen Study Results, FDA Filing Still on for Mid Year

The company presents at the J.P. Morgan Healthcare Conference on Thursday.

Jim Cramer's 'Mad Money' Recap: Knowing Where to Look for Bargains

Jim Cramer's 'Mad Money' Recap: Knowing Where to Look for Bargains

The markets are presenting a buying opportunity at current levels, but only if you know which stocks to buy, Cramer says.

Prosensa Holding (RNA) Upgraded From Sell to Hold

Prosensa Holding (RNA) Upgraded From Sell to Hold

Prosensa Holding (RNA) has been upgraded by TheStreet Ratings from Sell to Hold with a ratings score of C-.

The Nominees for Best Biotechnology Co. CEO of 2014 Are...

The Nominees for Best Biotechnology Co. CEO of 2014 Are...

The CEOs of Exact Sciences, Idenix Pharma, Prosensa, Agios, Bluebird Bio and InterMune vie for the coveted title of Best Biotech CEO

Biotech Stock Mailbag: Aethlon Medical, Oxigene, Sarepta

Biotech Stock Mailbag: Aethlon Medical, Oxigene, Sarepta

Biotech columnist Adam Feuerstein answers readers' questions about health care.

Jim Cramer's Five Best Stock Picks for the Biotech Sector

Jim Cramer's Five Best Stock Picks for the Biotech Sector

TheStreet's Jim Cramer has selected 12 sectors where he thinks investors should put their money. Biotech stocks have had a 'monstrous' year. Here are Cramer's best picks.

SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Prosensa Holding N.V. And Encourages Investors To Contact The Firm For Additional Information

SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Prosensa Holding N.V. And Encourages Investors To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of...

Prosensa (RNA) Highlighted As Today's Perilous Reversal Stock

Prosensa (RNA) Highlighted As Today's Perilous Reversal Stock

Trade-Ideas LLC identified Prosensa (RNA) as a "perilous reversal" (up big yesterday but down big today) candidate

INVESTOR ALERT: Faruqi & Faruqi, LLP Announces The Investigation Of Prosensa Holding N.V. (RNA) Over The Proposed Sale Of The Company To BioMarin Pharmaceutical Inc.

INVESTOR ALERT: Faruqi & Faruqi, LLP Announces The Investigation Of Prosensa Holding N.V. (RNA) Over The Proposed Sale Of The Company To BioMarin Pharmaceutical Inc.

Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Prosensa Holding N.

SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Prosensa Holding N.V. And Encourages Investors To Contact The Firm For Additional Information

SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Prosensa Holding N.V. And Encourages Investors To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of...

S&P 500 Little Changed Amid Uncertainty Over U.S. Economic Growth

S&P 500 Little Changed Amid Uncertainty Over U.S. Economic Growth

Investors continue to celebrate stimulus measures announced by China's central bank and the European Central Bank late last week.

S&P 500 Holds at Record Highs as Global Optimism Gives Support

S&P 500 Holds at Record Highs as Global Optimism Gives Support

Stocks flirt with intraday record highs and maintain recent buoyancy as global optimism combines with seasonal cheer.

U.S. Stocks Kick Off Thanksgiving Week Rally Amid Global Optimism

U.S. Stocks Kick Off Thanksgiving Week Rally Amid Global Optimism

Stocks climb as celebrations over stimulus measures out of China and Europe continue to boost markets.

November 24 Premarket Briefing: 10 Things You Should Know

November 24 Premarket Briefing: 10 Things You Should Know

U.S. stock futures rise; Symantec uncovers a sophisticated spying tool; a report says Tesla and BMW are in talks about a battery alliance; BioMarin buys Prosensa.

BioMarin Expands Reach by Buying Prosensa for Up to $840 Million

BioMarin Expands Reach by Buying Prosensa for Up to $840 Million

BioMarin is betting that its experience in securing approvals for "orphan-disease" drugs can help Prosensa win approval for drisapersen, an experimental treatment for Duchenne muscular dystrophy.

Cure Duchenne And Prosensa To Present Collaboration At Partnering For Cures Conference

Cure Duchenne And Prosensa To Present Collaboration At Partnering For Cures Conference

CureDuchenne and Prosensa Holding N.V.

Biotech Stock Mailbag: Prosensa, Sarepta, Arena Pharma, Hemispherx

Biotech Stock Mailbag: Prosensa, Sarepta, Arena Pharma, Hemispherx

Biotech columnist Adam Feuerstein answers readers' questions about health care.

Sarepta Shares Falls on Duchenne Drug Approval Filing Delay

Sarepta Shares Falls on Duchenne Drug Approval Filing Delay

FDA concerns about the reliability of clinical data for a muscular dystrophy drug raise investor concerns about Sarepta's path toward approval.